Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Propylene glycol

Classification: B

Drug products: Locobase LPL, Oviderm, Propyderm®, Propylenglykol i Decubal® kräm APL, Propylenglykol i Essex B kräm APL, Propylenglykol i Essex kräm APL, Propylenglykol i Locobase® kräm APL, Propylenglykol i Locobase® lotion APL, Propyless®, Propysal

ATC code: D02AX

Substances: propylene glycol

Summary

Published controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of topical propylene glycol are lacking.

The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical propylene glycol have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of topical propylene glycol have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding the adverse effects of topical propylene glycol have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2015-11-20

References

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk
Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.] länk

Authors: Maria Enghag, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson